Peter Bach, new Delfi Diagnostics CMO (Michael Loccisano/Getty Images for New York Times)

Out­spo­ken drug pric­ing re­searcher Pe­ter Bach takes CMO gig at liq­uid biop­sy start­up

Af­ter spend­ing more than a decade crit­i­ciz­ing the in­dus­try over drug pric­ing, Memo­r­i­al Sloan Ket­ter­ing’s out­spo­ken re­searcher Pe­ter Bach is jump­ing over to the C-suite of a liq­uid biop­sy start­up.

Bach, known for his frank tweets and fre­quent ed­i­to­ri­als, is tak­ing the CMO role at Delfi Di­ag­nos­tics, a Bal­ti­more-based biotech that’s look­ing for a bet­ter way to screen the blood for can­cer. The com­pa­ny snagged $100 mil­lion at the be­gin­ning of the year, and a cou­ple months ago ini­ti­at­ed a na­tion­al tri­al for lung can­cer screen­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.